CAS 81624-55-7
:N,N,N',N'-tétrakis[(6-méthyl-1H-benzimidazol-2-yl)méthyl]éthane-1,2-diamine
NSC-348884
CAS :Formule :C38H40N10Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :636.7912Ref: IN-DA00G3SN
1gÀ demander1mg38,00€5mg43,00€10mg67,00€25mg90,00€50mg132,00€100mg179,00€250mg217,00€NSC348884
CAS :NSC348884, a nucleophosmin inhibitor, disrupts oligomers, induces apoptosis, and inhibits cancer cell growth (IC50: 1.7-4.0 μM).Formule :C38H40N10Degré de pureté :98.69% - 99.91%Couleur et forme :SolidMasse moléculaire :636.79Ref: TM-T6909
2mg39,00€5mg58,00€10mg90,00€25mg172,00€50mg280,00€100mg405,00€500mg888,00€1mL*10mM (DMSO)80,00€NSC348884
CAS :NSC348884 is a novel anti-cancer drug that is an inhibitor of RNA polymerase. It has been shown to inhibit cellular transformation and viability in human leukemia HL-60 cells and prostate cancer cells, as well as inducing apoptosis. The mechanism of action of NSC348884 may be mediated through the induction of reactive oxygen species (ROS), activation of caspases, and modulation of signal transduction pathways. NSC348884 has also been shown to induce a variety of transcriptional effects on tumor cells, including upregulation or downregulation of genes involved in cell cycle regulation and apoptosis. This drug is also efficacious against brain tumors with malignant characteristics and breast cancer cells that are resistant to monoclonal antibody therapy.
Formule :C38H40N10Degré de pureté :Min. 95%Masse moléculaire :636.79 g/mol




